The inhibition of B7-H3 signaling to be used alone or in combination with other treatments is expected to contribute to improvements in clinical practice and benefit cancer patients, although validation of the safety and efficacy of targeted B7-H3 treatment remains unconfirmed. Here, CD276 is linked to cancer.